利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

46 条记录 (耗时 0.036 秒)

    MODIFIED COAGULATION FACTORS WITH PROLONGED IN VIVO HALF-LIFE
    11.
    发明申请
    MODIFIED COAGULATION FACTORS WITH PROLONGED IN VIVO HALF-LIFE 有权
    改良的凝血因子与生殖健康生活息息相关

    公开(公告)号：US20100120664A1

    公开(公告)日：2010-05-13

    申请号：US12520840

    申请日：2007-12-21

    申请人： Stefan Schulte ,  Thomas Weimer ,  Hubert Metzner

    发明人： Stefan Schulte ,  Thomas Weimer ,  Hubert Metzner

    IPC分类号： A61K38/16 ,  C07K14/745 ,  C07K14/755 ,  C07H21/00 ,  C12N15/74 ,  C12N5/10 ,  C12P21/00 ,  A61P7/04

    CPC分类号： C07K14/755 ,  C07K14/745 ,  C07K14/765 ,  C07K16/18 ,  C07K2319/31

    摘要： The present invention relates to nucleic acid sequences coding for modified coagulation factors, preferably coagulation factor VIII, and their derivatives; recombinant expression vectors containing such nucleic acid sequences; host cells transformed with such recombinant expression vectors; and recombinant polypeptides and derivatives coded for by said nucleic acid sequences, whereby said recombinant polypeptides and derivatives have biological activities and prolonged in vivo half-lives compared to the unmodified wild-type proteins. The invention also relates to corresponding sequences that result in improved in vitro stability. The present invention further relates to processes for the manufacture of such recombinant proteins and their derivatives. The invention also relates to a transfer vector for use in human gene therapy, which comprises such nucleic acid sequences.

    摘要翻译： 本发明涉及编码改性凝血因子，优选凝血因子VIII及其衍生物的核酸序列; 含有该核酸序列的重组表达载体; 用这些重组表达载体转化的宿主细胞; 和由所述核酸序列编码的重组多肽和衍生物，其中与未修饰的野生型蛋白相比，所述重组多肽和衍生物具有生物学活性和延长的体内半衰期。 本发明还涉及导致体外稳定性改善的相应序列。 本发明还涉及制备这些重组蛋白及其衍生物的方法。 本发明还涉及用于人基因治疗的转移载体，其包含这样的核酸序列。

    Proteolytically cleavable fusion proteins with high molar specific activity
    13.
    发明申请
    Proteolytically cleavable fusion proteins with high molar specific activity 审中-公开
    具有高摩尔比活性的蛋白水解切割融合蛋白

    公开(公告)号：US20090042787A1

    公开(公告)日：2009-02-12

    申请号：US11812016

    申请日：2007-06-14

    申请人： Hubert Metzner ,  Thomas Weimer ,  Stefan Schulte

    发明人： Hubert Metzner ,  Thomas Weimer ,  Stefan Schulte

    IPC分类号： A61K38/16 ,  C07K19/00 ,  C07H21/04 ,  C12N15/63 ,  A61P7/00 ,  A61K31/711 ,  C12N5/10 ,  C12P21/00

    CPC分类号： C07K14/745 ,  A61K38/00 ,  C07K14/755 ,  C07K2319/31 ,  C12N9/6424 ,  C12N9/6472

    摘要： The invention relates to therapeutic fusion proteins in which a coagulation factor is fused to a half-life enhancing polypeptide, and in which both are connected by a linker peptide that is proteolytically cleavable. The cleavage of such linkers liberates the coagulation factor from activity-compromising steric hindrance caused by the half-life enhancing polypeptide and thereby allows the generation of fusion proteins may show relatively high molar specific activity when tested in coagulation-related assays. Furthermore, the fact that the linker is cleavable can enhance the rates of inactivation and/or elimination after proteolytic cleavage of the peptide linker compared to the rates measured for corresponding therapeutic fusion proteins linked by the non-cleavable linker having the amino acid sequence GGGGGGV (SEQ ID NO: 94).

    摘要翻译： 本发明涉及治疗融合蛋白，其中凝血因子与半衰期增强多肽融合，并且其中两者通过可蛋白水解切割的接头肽连接。 这种接头的切割将凝血因子从半衰期增强多肽引起的活性损害的空间位阻释放，从而允许融合蛋白的产生在凝血相关测定中测试时可显示相对高的摩尔比活性。 此外，与通过具有氨基酸序列GGGGGGV的不可切割接头连接的相应治疗性融合蛋白的测量速率相比，接头可切割的事实可增加肽接头的蛋白水解切割后的失活和/或消除速率（ SEQ ID NO：94）。

    Modified coagulation factors with prolonged in vivo half-life
    14.
    发明授权
    Modified coagulation factors with prolonged in vivo half-life 有权
    改性凝血因子具有延长的体内半衰期

    公开(公告)号：US08754194B2

    公开(公告)日：2014-06-17

    申请号：US12520840

    申请日：2007-12-21

    申请人： Stefan Schulte ,  Thomas Weimer ,  Hubert Metzner

    发明人： Stefan Schulte ,  Thomas Weimer ,  Hubert Metzner

    IPC分类号： A61K38/37 ,  C07K1/00

    CPC分类号： C07K14/755 ,  C07K14/745 ,  C07K14/765 ,  C07K16/18 ,  C07K2319/31

    摘要： The present invention relates to nucleic acid sequences coding for modified coagulation factors, preferably coagulation factor VIII, and their derivatives; recombinant expression vectors containing such nucleic acid sequences; host cells transformed with such recombinant expression vectors; and recombinant polypeptides and derivatives coded for by said nucleic acid sequences, whereby said recombinant polypeptides and derivatives have biological activities and prolonged in vivo half-lives compared to the unmodified wild-type proteins. The invention also relates to corresponding sequences that result in improved in vitro stability. The present invention further relates to processes for the manufacture of such recombinant proteins and their derivatives. The invention also relates to a transfer vector for use in human gene therapy, which comprises such nucleic acid sequences.

    摘要翻译： 本发明涉及编码改性凝血因子，优选凝血因子VIII及其衍生物的核酸序列; 含有该核酸序列的重组表达载体; 用这些重组表达载体转化的宿主细胞; 和由所述核酸序列编码的重组多肽和衍生物，其中与未修饰的野生型蛋白相比，所述重组多肽和衍生物具有生物活性和延长的体内半衰期。 本发明还涉及导致体外稳定性改善的相应序列。 本发明还涉及制备这些重组蛋白及其衍生物的方法。 本发明还涉及用于人基因治疗的转移载体，其包含这样的核酸序列。

    Proteolytically cleavable fusion proteins with high molar specific activity
    16.
    发明授权
    Proteolytically cleavable fusion proteins with high molar specific activity 有权
    具有高摩尔比活性的蛋白水解切割融合蛋白

    公开(公告)号：US07939632B2

    公开(公告)日：2011-05-10

    申请号：US12000739

    申请日：2007-12-17

    申请人： Hubert Metzner ,  Thomas Weimer ,  Stefan Schulte

    发明人： Hubert Metzner ,  Thomas Weimer ,  Stefan Schulte

    IPC分类号： A61K38/36 ,  A61K38/38 ,  A61K38/48 ,  C07K14/76

    CPC分类号： C12N9/6437 ,  A61K38/00 ,  A61K48/00 ,  C07K14/745 ,  C07K14/755 ,  C07K14/76 ,  C07K14/765 ,  C07K2319/31 ,  C07K2319/50 ,  C12N9/6424 ,  C12N9/6443 ,  C12N9/6472 ,  C12Y304/21021 ,  C12Y304/21022

    摘要： The invention relates to therapeutic fusion proteins in which a coagulation factor is fused to a half-life enhancing polypeptide, and in which both are connected by a linker peptide that is proteolytically cleavable. The cleavage of such linkers liberates the coagulation factor from activity-compromising steric hindrance caused by the half-life enhancing polypeptide and thereby allows the generation of fusion proteins may show relatively high molar specific activity when tested in coagulation-related assays. Furthermore, the fact that the linker is cleavable can enhance the rates of inactivation and/or elimination after proteolytic cleavage of the peptide linker compared to the rates measured for corresponding therapeutic fusion proteins linked by the non-cleavable linker having the amino acid sequence GGGGGGV.

    摘要翻译： 本发明涉及治疗融合蛋白，其中凝血因子与半衰期增强多肽融合，并且其中两者通过可蛋白水解切割的接头肽连接。 这种接头的切割将凝血因子从半衰期增强多肽引起的活性损害的空间位阻释放，从而允许融合蛋白的产生在凝血相关测定中测试时可显示相对高的摩尔比活性。 此外，与通过具有氨基酸序列GGGGGGV的不可切割接头连接的相应治疗性融合蛋白测量的速率相比，接头可切割的事实可增加肽接头的蛋白水解切割后的失活和/或消除速率。